Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2004

01-12-2004 | Original Paper

p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan

Authors: For-Wey Lung, Tai-Min Lee, Bih-Ching Shu, Fu-Hsin Chang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2004

Login to get access

Abstract

Purpose

The p53 tumor suppressor gene plays two important roles in genomic stability: blocking cell proliferation after DNA damage until it has been repaired, and starting apoptosis if the damage is too critical. A recent report suggests that a polymorphism of the p53 tumor suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in the malignant transformation of colorectal adenoma to cancer.

Methods

In our study, the samples consisted of 150 patients were analyzed for the mutation in the p53 gene. The age of 150 patients (46 women and 104 men) ranged from 30 to 91 years (mean age 68.46 years).

Results

The polymorphism showed 52.04% mutant in the codon 72 of exon 4 in the Taiwanese population. Both of the chi-square for trend test (chi-square=4.97, p=0.034) and logistic regression (p=0.037, odds ratio=1.699) showed significant differences in the distribution of polymorphism of codon 72 in the p53 gene and Dukes classification of colorectal cancer.

Conclusions

There were significant relationship between the polymorphism of codon 72 and the malignancy of colorectal cancer in Taiwanese population. There is 1.70 times in each grade change (Dukes A–D) more risk of CCC polymorphism than that of CCG polymorphism of codon 72 of exon 4.
Literature
go back to reference Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997) The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMed Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B (1997) The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4:239–245PubMed
go back to reference Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW (2003) Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 19:151–158PubMed Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW (2003) Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 19:151–158PubMed
go back to reference Fearon ER, Hamilton SR, Vogelstein B (1987) Clonal analysis of human colorectal tumors. Science 328:193–197 Fearon ER, Hamilton SR, Vogelstein B (1987) Clonal analysis of human colorectal tumors. Science 328:193–197
go back to reference Hao XP, Ilyas M, Talbot IC (1997) Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 65:140–145PubMed Hao XP, Ilyas M, Talbot IC (1997) Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 65:140–145PubMed
go back to reference Hao XP, Frayling IM, Sgouros JG, Du MQ, Willcocks TC, Talbot IC, Tomlinson IPM (2002) The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Int J Gastroenterol Hepatol 56:834–839 Hao XP, Frayling IM, Sgouros JG, Du MQ, Willcocks TC, Talbot IC, Tomlinson IPM (2002) The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Int J Gastroenterol Hepatol 56:834–839
go back to reference Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650–4656PubMed Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650–4656PubMed
go back to reference Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMed Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMed
go back to reference Jin X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205–2208PubMed Jin X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205–2208PubMed
go back to reference Knudson AG (1985) Hereditary cancer, oncogens, and antioncogenes. Cancer Res 45:1437–1743PubMed Knudson AG (1985) Hereditary cancer, oncogens, and antioncogenes. Cancer Res 45:1437–1743PubMed
go back to reference Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961–963PubMed Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961–963PubMed
go back to reference O’Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJEMF (2001) P53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 54:539–542CrossRefPubMed O’Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJEMF (2001) P53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 54:539–542CrossRefPubMed
go back to reference Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766–2770PubMed Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766–2770PubMed
go back to reference Pignatelli M, Stamp GW, Kafiri G, Lane D, Bodmer WF (1992) Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50:683–688PubMed Pignatelli M, Stamp GW, Kafiri G, Lane D, Bodmer WF (1992) Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 50:683–688PubMed
go back to reference Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ (1998) P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352:871–872CrossRefPubMed Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ (1998) P53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 352:871–872CrossRefPubMed
go back to reference Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS (1988) Reduced growth-factor requirement of keloid derived fibroblasts may account for tumor growth. Proc Natl Acad Sci USA 85:587–591PubMed Russell SB, Trupin KM, Rodriguez-Eaton S, Russell JD, Trupin JS (1988) Reduced growth-factor requirement of keloid derived fibroblasts may account for tumor growth. Proc Natl Acad Sci USA 85:587–591PubMed
go back to reference Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237–241PubMed Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55:237–241PubMed
go back to reference Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) P53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316PubMed Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) P53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316PubMed
go back to reference Sorensen DM, Lewark TM, Haney JL, Meyers AD, Krause G, Franklin WA (1997) Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. Arch Otolaryngol Head Neck Surg 123:503–506PubMed Sorensen DM, Lewark TM, Haney JL, Meyers AD, Krause G, Franklin WA (1997) Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. Arch Otolaryngol Head Neck Surg 123:503–506PubMed
go back to reference Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229–334CrossRefPubMed Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229–334CrossRefPubMed
go back to reference Ulrik L, Hanna F, Nikos P, Adel G, Henrik Z, Hans O (2000) Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer 88:2661–2667CrossRefPubMed Ulrik L, Hanna F, Nikos P, Adel G, Henrik Z, Hans O (2000) Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer 88:2661–2667CrossRefPubMed
go back to reference Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999) Prognostic significance of p53 codon 72 polymorphism in lung carcinoma. Eur J Cancer 5:226–230CrossRef Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999) Prognostic significance of p53 codon 72 polymorphism in lung carcinoma. Eur J Cancer 5:226–230CrossRef
Metadata
Title
p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan
Authors
For-Wey Lung
Tai-Min Lee
Bih-Ching Shu
Fu-Hsin Chang
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0605-4

Other articles of this Issue 12/2004

Journal of Cancer Research and Clinical Oncology 12/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.